Showing results (71-80 of 132) with videos related to
Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2018
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyManish A Shah, Alexander Starodub, Sunil Sharma, et al.Blood|September 15, 2022
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemiaRobert J Kreitman, Philippe Moreau, Farhad Ravandi, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.JCO Precision Oncology|January 24, 2025
Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 TrialSun Young Rha, Yanqiao Zhang, Anneli Elme, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2022
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose ChemotherapyZev A Wainberg, Arun S Singh, Gottfried E Konecny, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumorsPhilippe L Bedard, Josep Tabernero, Filip Janku, et al.The Oncologist|March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.Journal for Immunotherapy of Cancer|July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trialKohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.Pageof 14